DHA / DOH / MOH exam (UAE) endocrinology & diabetes questions

Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells, producing an acute presentation with weight loss, ketosis, low body mass index, low C-peptide reflecting insufficient endogenous insulin production, and positive islet autoantibodies such as GAD antibody. Type 2 diabetes typically occurs in overweight individuals with insulin resistance, preserved or elevated C-peptide, and negative autoantibodies. MODY presents with a strong family history and preserved C-peptide without antibodies. Steroid-induced diabetes requires a history of glucocorticoid exposure, which is absent here.

• B. There is no history of glucocorticoid use to support this diagnosis.
• C. MODY lacks autoantibodies and typically has a strong autosomal dominant family history, both absent here.
• D. Type 2 diabetes would show preserved or high C-peptide and negative autoantibodies, not low C-peptide with positive GAD antibody.

Maturity-onset diabetes of the young (MODY) should be suspected when diabetes presents before age 25, there is a strong multigenerational autosomal dominant family history, autoantibodies are negative, C-peptide is preserved, and the patient is not obese. Many MODY subtypes, particularly HNF1A-MODY, respond well to low-dose sulfonylureas rather than insulin, consistent with the family's treatment pattern. Type 1 diabetes would show antibody positivity and low C-peptide. Type 2 diabetes is less likely given the lean body habitus, young age and vertical family transmission pattern typical of a single-gene defect. LADA occurs in adults with slowly progressive antibody-positive disease, which is excluded by negative antibodies here.

• B. LADA requires positive islet autoantibodies, which are absent in this patient.
• C. Type 1 diabetes would show positive autoantibodies and low C-peptide, not preserved C-peptide with negative antibodies.
• D. The lean body habitus, young age, and strong vertical family history favor a monogenic cause over typical type 2 diabetes.

Metformin remains the preferred first-line pharmacologic agent for most patients with newly diagnosed type 2 diabetes, according to ADA and EASD-aligned guidance, due to its efficacy, safety profile, weight neutrality, low hypoglycemia risk, and low cost. It is appropriate in this patient given preserved renal function and no contraindications. SGLT2 inhibitors or GLP-1 receptor agonists are prioritized first-line specifically in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, none of which are present here. Sulfonylureas carry a higher risk of hypoglycemia and weight gain, and insulin is reserved for more severe hyperglycemia or when oral agents fail.

• A. Insulin is not required as initial therapy for this moderate degree of hyperglycemia without acute decompensation.
• B. Sulfonylureas are not first-line due to higher hypoglycemia risk and weight gain compared with metformin.
• C. SGLT2 inhibitors are prioritized first-line mainly in patients with cardiovascular, renal, or heart failure indications, which are absent here.

Metformin primarily reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, without stimulating insulin secretion, so it does not cause hypoglycemia as monotherapy. It is renally cleared, and reduced clearance at low eGFR increases the risk of lactic acidosis accumulation. Current guidelines recommend avoiding initiation below eGFR 45 mL/min/1.73m2 and stopping the drug entirely once eGFR falls below 30 mL/min/1.73m2. This patient's eGFR of 27 mL/min/1.73m2 falls below that cutoff, so metformin should be discontinued.

• A. This describes sulfonylureas, not metformin, and the cutoff is inaccurate.
• B. Metformin decreases, not increases, hepatic glucose output, and the cutoff given is incorrect.
• D. This describes SGLT2 inhibitors, not metformin.

In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, current guidelines recommend adding an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit, independent of baseline HbA1c or additional glucose-lowering need. These agents have been shown in large cardiovascular outcome trials to reduce major adverse cardiovascular events, cardiovascular death, and in the case of SGLT2 inhibitors, heart failure hospitalization. This patient's prior myocardial infarction places him in a high cardiovascular risk category, making this class preferred over agents with neutral or adverse cardiovascular profiles.

• A. Thiazolidinediones can worsen heart failure risk and are avoided in patients with cardiovascular disease.
• B. DPP-4 inhibitors are cardiovascular neutral and do not offer the proven benefit required in this high-risk patient.
• D. Sulfonylureas have a neutral to potentially adverse cardiovascular profile and are not preferred in this setting.

SGLT2 inhibitors can precipitate euglycemic diabetic ketoacidosis, in which ketoacidosis occurs despite near-normal or only mildly elevated blood glucose. The mechanism involves increased glucosuria lowering blood glucose while increased glucagon and lipolysis drive ketone production, and this risk is amplified by surgical stress, fasting, and reduced carbohydrate intake. The combination of a high anion gap metabolic acidosis, significant ketonuria, and a blood glucose level below the usual DKA threshold of 13.9 mmol/L in a patient on an SGLT2 inhibitor perioperatively is classic for this diagnosis. SGLT2 inhibitors should be withheld for at least 3 days before elective surgery to prevent this complication.

• A. Pancreatitis does not typically cause this degree of metabolic acidosis with significant ketonuria.
• B. Hyperosmolar hyperglycemic state requires markedly elevated glucose, usually above 33 mmol/L, which is not present here.
• D. Lactic acidosis would show an elevated serum lactate rather than prominent ketonuria as the dominant finding.

SGLT2 inhibitors block sodium-glucose cotransporter-2 in the proximal renal tubule, reducing glucose reabsorption and causing glucosuria. The resulting glucose-rich urogenital environment promotes fungal overgrowth, causing genital mycotic infections, and rarely this can progress to Fournier's gangrene, a necrotizing fasciitis of the perineum. The presentation of fever, perineal pain, swelling and crepitus in a patient recently started on an SGLT2 inhibitor is a recognized and serious adverse effect requiring immediate surgical referral and drug discontinuation. This is a boxed warning for this drug class.

• A. DPP-4 inhibitors act by this mechanism and are not associated with Fournier's gangrene.
• B. Sulfonylureas, not SGLT2 inhibitors, act by this mechanism and this does not explain necrotizing infection.
• D. This describes thiazolidinediones, which cause fluid retention but not this infectious complication.

Marked hyperglycemia with catabolic features (unintentional weight loss, polyuria, polydipsia) and a very high HbA1c (≥10%) indicate significant insulin deficiency, regardless of ketone status. Guidelines recommend initiating insulin therapy in such patients to rapidly correct glucotoxicity, after which oral agents may later be introduced or insulin tapered once glycemic control improves. Oral monotherapy is too slow to control severe hyperglycemia with catabolic symptoms. This approach reduces the risk of progression to diabetic ketoacidosis or hyperosmolar state.

• B. Dual oral therapy does not provide the rapid glycemic control needed in this catabolic state.
• C. Metformin alone is inadequate for severe symptomatic hyperglycemia with catabolic features.
• D. A GLP-1 agonist alone is insufficient for this degree of hyperglycemia with weight loss and catabolism.

Current guidelines recommend individualizing HbA1c targets based on age, life expectancy, comorbidities, functional status and hypoglycemia risk. A young, newly diagnosed patient without complications benefits from a tighter target (6.5-7.0%) to reduce long-term microvascular and macrovascular risk. A frail elderly patient with cognitive impairment and falls is at high risk of harm from hypoglycemia, so a looser target (8.0-8.5%) is preferred to minimize that risk while avoiding symptomatic hyperglycemia.

• A. This reverses the appropriate targets; the frail elderly patient needs the looser target, not the young patient.
• B. A target this tight for both patients would expose the frail elderly patient to unacceptable hypoglycemia risk.
• D. A loose target for the young patient forgoes the long-term benefit of tight control, and is overly permissive for someone with no complications.

This patient meets criteria for prediabetes (impaired fasting glucose and HbA1c 5.7-6.4%). First-line management is structured lifestyle intervention, targeting at least 7% weight loss and 150 minutes per week of moderate-intensity physical activity, which has been shown to reduce progression to type 2 diabetes by over 50% in major prevention trials. Pharmacologic therapy is reserved for higher-risk individuals who fail lifestyle measures or have additional risk factors such as obesity with BMI above 35 kg/m² or prior gestational diabetes.

• A. Metformin may be considered as an adjunct in higher-risk prediabetic patients but is not the first-line step here.
• C. Bariatric surgery is not indicated for prediabetes at this BMI and without failed conservative measures.
• D. SGLT2 inhibitors are not indicated for prediabetes; they are used for established type 2 diabetes with specific comorbidities.

A basal-bolus regimen most closely mimics physiologic insulin secretion and is the preferred regimen for newly diagnosed type 1 diabetics. Long-acting insulin (such as glargine or detemir) provides steady basal coverage to suppress hepatic gluconeogenesis between meals and overnight, while rapid-acting insulin (such as lispro, aspart or glulisine) is given before meals to cover postprandial glucose excursions. This combination allows flexible dosing and better glycemic control than fixed premixed regimens, especially in type 1 diabetes where endogenous insulin secretion is absent.

• A. Premixed insulin offers less flexibility and is generally reserved for select type 2 diabetic patients, not standard in new type 1 diabetes.
• B. Basal insulin alone fails to cover postprandial glucose excursions, which is essential in type 1 diabetes.
• C. Bolus insulin alone without basal coverage leaves the patient without steady background insulin, risking ketosis between meals and overnight.

Sick day rules for type 1 diabetes emphasize that basal insulin should never be stopped, even if the patient is not eating, because illness increases counter-regulatory hormones and insulin requirements, and stopping insulin risks diabetic ketoacidosis. Additional correction doses of rapid-acting insulin should be given based on glucose and ketone levels, with monitoring every 2-4 hours. Fluids and carbohydrate intake should be maintained if possible, and the patient should seek emergency care if ketones rise, vomiting persists or glucose remains uncontrolled.

• A. Stopping all insulin during illness with ketosis risks precipitating diabetic ketoacidosis.
• B. Basal insulin must be continued regardless of oral intake to prevent ketosis during illness.
• D. Reducing basal insulin and omitting rapid-acting insulin ignores the need for correction doses in the setting of hyperglycemia and ketosis.

In an unconscious or unresponsive hypoglycemic patient, oral glucose administration is unsafe due to the risk of aspiration. When intravenous access is not immediately available, intramuscular glucagon is the appropriate first-line treatment, as it rapidly mobilizes hepatic glycogen stores to raise blood glucose. Once intravenous access is established, dextrose can be given. In contrast, a conscious, cooperative hypoglycemic patient should receive oral fast-acting carbohydrate such as glucose tablets or juice.

• B. Oral fluids are contraindicated in an unresponsive patient due to aspiration risk.
• C. Oral glucose gel in an unconscious patient risks aspiration and is unsafe.
• D. Delaying treatment risks hypoglycemic brain injury; immediate glucagon should be given while awaiting further help.

Lipohypertrophy results from repeated insulin injections into the same site, causing localized adipocyte hypertrophy and fibrosis, which presents as a firm, non-tender, rubbery swelling. Insulin injected into these areas is absorbed erratically and unpredictably, leading to unexplained glycemic variability despite unchanged doses. Management involves patient education on proper injection site rotation and avoiding the affected area until it resolves, which can take months. This is a common and often under-recognized complication in long-term insulin users who favor a particular injection site.

• A. Insulin resistance from obesity typically causes gradually rising insulin requirements, not a localized swelling with erratic absorption from a single site.
• B. Insulin allergy presents with pruritic, erythematous or urticarial skin reactions, not a firm rubbery swelling with normal skin color.
• D. Anti-insulin antibodies are a rare cause of insulin resistance and do not produce a localized subcutaneous swelling.

Recurrent nocturnal hypoglycemia with stable bedtime glucose levels indicates that the basal insulin dose is excessive relative to overnight requirements, since basal insulin is the main driver of glucose levels during sleep when no food is being absorbed. The appropriate response is to reduce the basal insulin dose, not to add calories or alter the regimen structure. Reviewing the dose is preferred over simply adding a snack, which only masks the underlying mismatch and promotes weight gain. Basal insulin titration based on fasting and overnight glucose patterns is a core principle of insulin management in type 1 diabetes.

• A. A bedtime snack treats the symptom without correcting the excess basal insulin dose causing it.
• C. Mealtime insulin aspart affects post-dinner glucose, not the overnight basal requirement, and would worsen the hypoglycemia.
• D. Switching regimens is unnecessary and premixed insulin offers less flexibility and a higher hypoglycemia risk than basal-bolus therapy.

This presentation fits hyperosmolar hyperglycemic state (HHS): markedly elevated glucose above 33 mmol/L, serum osmolality above 320 mOsm/kg, absent or minimal ketones, and near-normal pH and bicarbonate. DKA requires significant ketosis and a metabolic acidosis with pH below 7.3 and bicarbonate below 18 mmol/L, neither of which is present here. HHS typically develops over days in older type 2 diabetics and presents with profound dehydration and neurological changes due to extreme hyperosmolality rather than acidosis. Distinguishing the two conditions matters because fluid deficits are larger in HHS and insulin requirements differ.

• A. DKA requires significant ketonemia and a pH below 7.3 with low bicarbonate, both absent in this patient.
• B. A mixed picture would show both significant ketosis and acidosis along with hyperosmolality, which is not seen here.
• C. Lactic acidosis would show a low pH with an elevated anion gap and lactate level, not a near-normal pH and bicarbonate.

The first priority in DKA management is restoring intravascular volume with isotonic 0.9% sodium chloride, especially in a patient with hypotension and tachycardia indicating significant dehydration and hypovolemic shock risk. Fluid resuscitation improves tissue perfusion, helps lower glucose through dilution, and reduces counter-regulatory hormone release before insulin therapy begins. Insulin should only be started after initial fluid resuscitation has begun, as giving insulin first can precipitate a rapid fall in osmolality and risk cardiovascular collapse or cerebral edema. Bicarbonate is not routinely given except in cases of severe acidosis with pH below 6.9 refractory to standard therapy.

• A. Insulin infusion should be started after initial fluid resuscitation has begun, not before, to avoid precipitating cardiovascular collapse.
• B. Bicarbonate is not first-line and is reserved for severe refractory acidosis with pH below 6.9.
• D. Subcutaneous insulin has unreliable absorption in the setting of dehydration and shock and is not used in acute DKA management.

Insulin therapy drives potassium intracellularly, and a serum potassium below 3.3 mmol/L during DKA treatment requires potassium replacement to prevent life-threatening arrhythmias and respiratory muscle weakness. Potassium chloride should be added to the intravenous fluids while continuing the insulin infusion, provided the patient has adequate urine output confirming preserved renal function. Insulin should not be stopped, since halting it would worsen ketosis and acidosis; instead, potassium is replaced alongside continued insulin therapy. Serum potassium must be monitored every one to two hours during the acute phase of DKA treatment.

• A. Calcium gluconate is used for hyperkalemia with ECG changes, not for hypokalemia.
• C. Stopping insulin would worsen ketosis and acidosis; the correct response is to add potassium while continuing insulin.
• D. Switching fluid type without addressing the potassium deficit does not correct the hypokalemia.

DKA resolution is defined biochemically by normalization of the metabolic acidosis: venous pH above 7.3, serum bicarbonate of 18 mmol/L or greater, and a normal anion gap (typically below 12 mmol/L), together with clearance of ketosis. These criteria confirm that the underlying ketoacidotic process has resolved, which is the actual therapeutic target, rather than glucose level alone. Glucose normalization occurs earlier than acidosis resolution and is not sufficient by itself to confirm resolution. Subcutaneous insulin should be started once these biochemical criteria are met, with the first subcutaneous dose given before stopping the insulin infusion to prevent a gap in insulin coverage.

• A. Subjective improvement does not reliably reflect the biochemical resolution of acidosis and ketosis.
• B. Glucose normalizes before the acidosis resolves and does not by itself confirm resolution of ketoacidosis.
• D. Tolerating oral fluids is reassuring but is not one of the defined biochemical criteria for DKA resolution.

Omission of basal insulin removes the background suppression of lipolysis, allowing free fatty acids to be mobilized and converted to ketone bodies in the liver, which precipitates ketoacidosis even if mealtime insulin is continued. This is a well-recognized precipitant of DKA, particularly in patients with cost or access barriers to insulin, and history taking should always include direct questions about insulin adherence and access. Identifying missed basal insulin as the cause directs both acute management and discharge counseling on insulin access and sick-day rules. Other precipitants such as infection or new-onset diabetes should also be actively sought, but the history here points specifically to insulin omission.

• B. No signs of infection are described in this history, and insulin resistance from infection is a separate precipitant.
• C. Dehydration is a consequence of the hyperglycemia and ketoacidosis in this case, not the initiating cause.
• D. Residual insulin secretion is minimal or absent in established type 1 diabetes, so carbohydrate intake alone would not be the primary driver here.

Because type 2 diabetes often has a long asymptomatic phase before diagnosis, retinopathy may already be present at presentation. Guidelines therefore recommend a comprehensive dilated eye examination at the time of diagnosis, followed by annual screening if the initial exam is normal. Earlier damage can be detected before visual symptoms occur, allowing timely laser or anti-VEGF therapy. Screening intervals may be extended in low-risk patients with good glycemic control, but this is individualized, not a fixed 2-5 year default.

• B. Waiting for symptoms misses the asymptomatic window when treatable retinopathy is most reversible.
• C. A 5-year delay is inappropriate in type 2 diabetes because retinopathy may be present at diagnosis.
• D. OCT every 6 months is not the first-line screening tool and is unnecessarily frequent and costly.

A urine albumin-to-creatinine ratio (UACR) between 30 and 300 mg/g, confirmed on two of three samples over 3-6 months, defines moderately increased albuminuria (previously called microalbuminuria, category A2), an early marker of diabetic kidney disease. This finding, combined with long-standing diabetes and a preserved eGFR, is consistent with early diabetic nephropathy rather than another renal cause. KDIGO staging uses both eGFR and UACR categories to grade chronic kidney disease. Confirmation on repeat testing avoids false positives from transient albuminuria due to fever, exercise, or infection.

• A. Nephrotic-range proteinuria corresponds to UACR above roughly 2200 mg/g (or urine protein above 3.5 g/day), far higher than this value.
• C. There are no urinary symptoms or pyuria to suggest infection, and albuminuria is not a typical UTI finding.
• D. A UACR of 45 mg/g is above the normal threshold of 30 mg/g and is clinically significant.

In diabetic patients with albuminuria, angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers) are first-line because they reduce intraglomerular pressure by dilating the efferent arteriole, lowering proteinuria independent of their blood pressure-lowering effect, and slow progression to end-stage renal disease. This renoprotective effect is distinct from other antihypertensive classes. SGLT2 inhibitors are now also recommended as an add-on for renoprotection in this setting, but an ACE inhibitor or ARB remains the foundational first agent when albuminuria is present. Serum creatinine and potassium should be monitored after initiation.

• B. Calcium channel blockers lower blood pressure but lack the specific antiproteinuric effect on the efferent arteriole.
• C. Thiazides help blood pressure control but do not provide the same renoprotective benefit in albuminuric diabetic kidney disease.
• D. Beta-blockers are not first-line for renoprotection in diabetic nephropathy and lack evidence for slowing albuminuria progression.

The clinical picture, symmetric burning pain with sensory loss and absent ankle reflexes in a patient with long-standing diabetes, is consistent with painful diabetic peripheral neuropathy, a clinical diagnosis supported by findings on examination. Guidelines recommend pregabalin, gabapentin, or duloxetine as first-line pharmacologic agents because they target neuropathic pain through calcium channel modulation or serotonin-norepinephrine reuptake inhibition. Simple analgesics such as NSAIDs are not effective for neuropathic pain. Opioids like tramadol are reserved for refractory cases due to dependence risk, and vitamin B12 is only indicated if a deficiency is confirmed.

• A. Tramadol is a second- or third-line option due to abuse potential and side effects, not first-line therapy.
• C. Vitamin B12 is appropriate only if deficiency is biochemically confirmed, not as empiric first-line therapy for diabetic neuropathic pain.
• D. NSAIDs act on inflammatory pain pathways and are not effective for neuropathic pain.

Loss of protective sensation on monofilament testing combined with absent pedal pulses identifies a high-risk diabetic foot, placing the patient at significantly increased risk of ulceration and amputation even without current skin breakdown. Current guidelines recommend referral to a podiatrist and/or vascular specialist for further evaluation, including ankle-brachial index testing and structured foot care education, rather than routine annual rescreening. Early referral allows preventive measures such as offloading footwear and vascular assessment before ulceration occurs. There is no sign of infection, so antibiotics are not indicated.

• B. Annual rescreening is insufficient given the high-risk findings; this patient needs specialist assessment now.
• C. Simple moisturizer advice with a 3-year interval grossly underestimates the risk indicated by sensory loss and absent pulses.
• D. There is no evidence of infection or ulceration, so antibiotics are not indicated.

Delayed gastric emptying (gastroparesis) with postprandial fullness, bloating, and vomiting of undigested food, together with orthostatic hypotension showing an inadequate compensatory heart rate rise, points to diabetic autonomic neuropathy affecting both gastrointestinal and cardiovascular autonomic fibers. A normal endoscopy excludes a structural cause for the gastric symptoms. The blunted heart rate response to standing, rather than a normal reflex tachycardia, reflects impaired cardiovascular autonomic reflexes. Management includes dietary modification, prokinetic agents for gastroparesis, and non-pharmacologic measures for orthostatic hypotension.

• A. Peptic ulcer disease would typically show mucosal abnormality on endoscopy, which is normal here.
• B. Pancreatitis presents with acute epigastric pain and elevated lipase, not chronic postprandial fullness with normal endoscopy.
• D. Hypothyroidism can cause constipation and bradycardia but does not explain orthostatic hypotension with blunted heart rate response or postprandial vomiting pattern.

Comprehensive annual diabetes care includes a dilated fundus examination for retinopathy screening, urine albumin-to-creatinine ratio for nephropathy screening, a foot examination with monofilament and pulse assessment for neuropathy and vascular risk, a fasting lipid profile for cardiovascular risk stratification, and blood pressure measurement, in addition to glycemic monitoring. This multi-system approach addresses the major microvascular and macrovascular complications of diabetes beyond glycemic control alone. HbA1c monitoring every 3-6 months is necessary but is only one component of comprehensive care. Routine thyroid function and chest X-ray are not part of the standard annual diabetes checklist unless clinically indicated.

• A. Weight and random glucose alone do not fulfill the required complication screening components.
• C. HbA1c monitoring alone, even if frequent, misses screening for retinopathy, nephropathy, neuropathy, and cardiovascular risk.
• D. Thyroid function and chest X-ray are not standard components of the routine annual diabetes complication screening checklist.

An elevated TSH with a free T4 that remains within the reference range defines subclinical hypothyroidism, reflecting mild thyroid failure that the pituitary is still able to compensate for by increasing TSH drive. Primary (overt) hypothyroidism requires a low free T4 alongside the raised TSH. This pattern is common and often due to early autoimmune (Hashimoto) thyroiditis. Management depends on TSH level, antibody status, symptoms, and patient factors such as pregnancy or cardiovascular risk.

• B. Sick euthyroid syndrome occurs in acute systemic illness and typically shows a low or normal TSH with variable T4/T3.
• C. Primary hypothyroidism requires a low free T4, which is normal here.
• D. Central hypothyroidism shows a low or inappropriately normal TSH with low free T4, not a raised TSH.

In older patients or those with cardiovascular disease, levothyroxine should be started at a low dose (such as 25-50 micrograms daily) and titrated gradually every 4-6 weeks based on TSH response, because rapid correction can precipitate angina or arrhythmia by increasing myocardial oxygen demand. Full weight-based replacement dosing is reserved for younger, healthier patients without cardiac disease. TSH is rechecked after each dose adjustment, allowing 4-6 weeks for equilibration given levothyroxine's long half-life.

• A. Combination therapy is not recommended as initial treatment and offers no proven advantage over levothyroxine alone.
• C. This dose is excessive and would risk iatrogenic thyrotoxicosis and cardiac events.
• D. Full-dose replacement risks cardiac ischemia in a patient with known coronary artery disease.

The clinical picture of diffuse goiter with bruit, exophthalmos, tachycardia, and suppressed TSH with elevated free T4 confirms Graves' disease, and the diagnosis is supported by a positive TSH receptor antibody (TRAb) assay. Carbimazole is the first-line antithyroid drug in non-pregnant adults because of its once-daily dosing and lower risk of hepatotoxicity compared with propylthiouracil. Propylthiouracil is reserved for the first trimester of pregnancy, thyroid storm, or carbimazole intolerance. Beta-blockers provide symptomatic control but do not treat the underlying hyperthyroidism.

• A. Radioactive iodine is a definitive option but not first-line initial pharmacotherapy, especially with active eye disease, which it can worsen.
• B. Propranolol alone controls adrenergic symptoms but does not address the underlying excess thyroid hormone synthesis.
• C. Propylthiouracil carries higher hepatotoxicity risk and is reserved for pregnancy (first trimester), thyroid storm, or carbimazole intolerance.

Fever and sore throat in a patient on an antithyroid drug should raise immediate suspicion for agranulocytosis, a rare but life-threatening idiosyncratic adverse effect that typically occurs within the first few months of therapy. The correct immediate action is to stop the drug and obtain an urgent complete blood count with differential to confirm or exclude neutropenia. If agranulocytosis is confirmed, the drug must be permanently discontinued and not substituted with the other thionamide, since cross-reactivity can occur. Prompt recognition and drug withdrawal reduce the risk of fatal sepsis.

• B. This presentation must never be dismissed as minor; it can represent life-threatening agranulocytosis.
• C. Switching to propylthiouracil risks cross-reactive agranulocytosis and should not be done without first confirming the blood count and stopping the current drug.
• D. Continuing the offending drug while treating with antibiotics ignores the need to stop the suspected cause and risks fatal sepsis.

This patient meets criteria for thyroid storm, a life-threatening endocrine emergency with fever, tachyarrhythmia, altered mental status, and a precipitating history of poorly controlled Graves' disease. Treatment requires a coordinated multimodal approach started immediately: a beta-blocker (propranolol) to control adrenergic symptoms and reduce peripheral T4-to-T3 conversion, a thionamide (propylthiouracil preferred for its additional blockade of peripheral conversion) to inhibit new hormone synthesis, iodine solution given at least one hour after the thionamide to block hormone release, and hydrocortisone to cover relative adrenal insufficiency and reduce peripheral conversion. Delaying treatment or using single-agent therapy carries a high risk of cardiovascular collapse and death.

• A. Supportive fluids alone fail to address the underlying hormone excess and adrenergic crisis, risking rapid deterioration.
• B. Radioactive iodine is contraindicated in thyroid storm and can worsen hormone release; it has no role in acute management.
• D. Monotherapy with carbimazole alone is inadequate for thyroid storm, which requires rapid multimodal therapy.

Painful thyroid swelling with a preceding viral illness, tenderness on examination, elevated inflammatory markers, and biochemical hyperthyroidism is typical of subacute (de Quervain) thyroiditis, caused by follicular disruption and release of preformed hormone rather than increased synthesis. A radioactive iodine uptake scan shows markedly low or absent uptake in subacute thyroiditis, in contrast to the diffusely increased uptake seen in Graves' disease, making it the most discriminating test. TSH receptor antibodies would be positive in Graves' disease but are not the most direct way to distinguish the two conditions when uptake imaging is available, and thyroglobulin is nonspecifically elevated in any process causing thyroid cell damage.

• A. Doppler ultrasound can show reduced vascularity in subacute thyroiditis but is less definitive than uptake scanning for distinguishing the two conditions.
• B. Thyroglobulin is elevated in both destructive thyroiditis and Graves' disease and does not reliably differentiate them.
• D. TRAb is specific for Graves' disease but a negative result does not directly demonstrate the mechanism distinguishing the two conditions as clearly as uptake imaging.

Thyroid hormone requirements increase in pregnancy due to higher thyroxine-binding globulin, increased metabolism by placental deiodinases, and transfer to the fetus, especially before the fetal thyroid becomes functional around 12 weeks. Guidelines recommend increasing the levothyroxine dose by approximately 25-30% as soon as pregnancy is confirmed, followed by TSH monitoring every 4 weeks during the first half of pregnancy with dose titration to a trimester-specific target. Untreated or undertreated maternal hypothyroidism is associated with risks including miscarriage, preeclampsia, and impaired fetal neurodevelopment.

• A. Liothyronine does not cross the placenta well and is not used for maternal hypothyroidism management in pregnancy.
• C. Levothyroxine is not teratogenic; stopping it risks harmful maternal and fetal hypothyroidism.
• D. Maintaining the pre-pregnancy dose risks maternal and fetal hypothyroidism because requirements rise in pregnancy.

Postpartum thyroiditis is a destructive lymphocytic thyroiditis causing release of preformed hormone, so radioactive iodine uptake is low during the thyrotoxic phase, unlike Graves' disease where uptake is diffusely increased due to active hormone synthesis. Graves' disease is driven by TSH-receptor stimulating antibodies, produces a vascular gland with an audible bruit, and can cause orbitopathy, none of which occur in postpartum thyroiditis. Postpartum thyroiditis typically follows a triphasic course of thyrotoxicosis, hypothyroidism, then recovery within 12 months. Distinguishing the two is essential because postpartum thyroiditis is managed with observation or beta-blockers, while Graves' disease requires antithyroid drugs.

• A. Stimulating immunoglobulins are the hallmark of Graves' disease, not postpartum thyroiditis.
• B. Exophthalmos is a feature of Graves' orbitopathy, not postpartum thyroiditis.
• D. A bruit reflects the hypervascularity of Graves' disease, absent in a destructive thyroiditis.

A low morning cortisol with hyponatremia and hyperkalemia strongly suggests primary adrenal insufficiency, but the ACTH (cosyntropin) stimulation test is the confirmatory investigation: failure of cortisol to rise appropriately (typically to above 500-550 nmol/L) after synthetic ACTH establishes adrenal failure. Plasma ACTH is also measured and is elevated in primary disease due to loss of cortisol negative feedback. A random afternoon cortisol lacks diagnostic cutoffs because of diurnal variation and cannot reliably confirm insufficiency. The dexamethasone suppression test and urinary free cortisol are used to evaluate cortisol excess, not deficiency.

• A. This test screens for Cushing's syndrome, the opposite condition of cortisol excess.
• B. A random afternoon level lacks validated cutoffs for diagnosing insufficiency due to diurnal variation.
• C. Urinary free cortisol assesses cortisol overproduction, not adrenal failure.

A suppressed or undetectable plasma ACTH in the setting of confirmed hypercortisolism indicates ACTH-independent Cushing's syndrome, most commonly caused by a cortisol-secreting adrenal adenoma; the autonomously produced cortisol suppresses pituitary ACTH through negative feedback. In contrast, pituitary corticotroph adenomas (Cushing's disease) and ectopic ACTH-secreting tumors both produce ACTH-dependent Cushing's syndrome with normal or elevated ACTH levels. Hypothalamic CRH excess is an exceedingly rare cause and would also raise ACTH, not suppress it. This distinction directs further workup, with low ACTH prompting adrenal imaging rather than pituitary MRI.

• A. A pituitary corticotroph adenoma drives ACTH production and would show a normal or high ACTH, not a suppressed level.
• C. Ectopic ACTH secretion raises plasma ACTH, which is inconsistent with the undetectable level described.
• D. CRH excess would stimulate pituitary ACTH release, raising rather than suppressing ACTH.

Resistant hypertension with unexplained hypokalemia should raise suspicion for primary hyperaldosteronism, and the plasma aldosterone-to-renin ratio is the recommended screening test; an elevated ratio with suppressed renin suggests autonomous aldosterone secretion, which is then confirmed with a salt-loading or saline infusion suppression test. Renin alone cannot distinguish primary from secondary causes of hyperaldosteronism without pairing it with the aldosterone level. Urinary catecholamines screen for pheochromocytoma, a different cause of resistant hypertension typically accompanied by paroxysmal symptoms rather than hypokalemia. The dexamethasone suppression test evaluates for Cushing's syndrome, not mineralocorticoid excess.

• A. Cortisol suppression testing screens for Cushing's syndrome, a different disorder.
• B. Renin alone, without the paired aldosterone level, cannot establish the diagnosis.
• C. Catecholamine testing evaluates for pheochromocytoma, which does not typically cause this hypokalemic, resistant hypertension pattern.

Paroxysmal hypertension with headache, sweating, and palpitations is classic for pheochromocytoma, and plasma (or urinary) fractionated metanephrines are the recommended first-line biochemical test due to their high sensitivity for catecholamine-secreting tumors. Metanephrines are continuously produced within tumor cells, giving them better diagnostic performance than measuring catecholamines themselves, which fluctuate episodically. The other tests screen for Cushing's syndrome or primary hyperaldosteronism, conditions that do not typically present with this paroxysmal triad. Once biochemically confirmed, cross-sectional imaging of the adrenal glands localizes the tumor.

• B. Urinary cortisol screens for Cushing's syndrome, not catecholamine-secreting tumors.
• C. The aldosterone-renin ratio screens for primary hyperaldosteronism, which presents with sustained hypertension and hypokalemia rather than paroxysms.
• D. Dexamethasone suppression testing is used to evaluate for cortisol excess, not catecholamine excess.

Dopamine agonists, with cabergoline preferred over bromocriptine for its superior efficacy and tolerability, are first-line therapy for prolactinoma regardless of tumor size, acting by stimulating pituitary D2 receptors to suppress prolactin secretion and shrink tumor volume. Most microprolactinomas respond well to medical therapy alone, normalizing prolactin and restoring menstrual cycles and fertility. Surgery is reserved for cases resistant or intolerant to dopamine agonists, or when there is acute visual compromise unresponsive to medical therapy. Radiotherapy is a later option for persistent or aggressive tumors, and levothyroxine is irrelevant since the TSH is normal, excluding a thyroid-related cause of hyperprolactinemia.

• A. Radiotherapy is a later-line option used for resistant or recurrent tumors.
• C. Surgery is reserved for cases refractory to or intolerant of medical therapy, not first-line treatment.
• D. A normal TSH excludes hypothyroidism as the cause, making thyroid hormone replacement inappropriate.

Growth hormone secretion is pulsatile, so a single random level is unreliable for diagnosis. Serum IGF-1 reflects integrated GH secretion over time and is used as a screening test; if elevated, the diagnosis is confirmed by failure of GH to suppress below 0.4 ng/mL during an oral glucose tolerance test. This dynamic test is the gold standard for biochemical confirmation of acromegaly. Pituitary MRI is performed after biochemical confirmation to localize a tumor, not to establish the diagnosis.

• A. Random GH levels are too variable due to pulsatile secretion to be diagnostic even if repeated.
• B. MRI should follow, not precede, biochemical confirmation and cannot establish hormonal excess on its own.
• C. This test evaluates for Cushing syndrome, not acromegaly.

Chronic glucocorticoid use for more than 3-4 weeks suppresses the hypothalamic-pituitary-adrenal axis, and abrupt cessation can precipitate adrenal crisis. A gradual, stepwise taper over weeks to months allows recovery of endogenous cortisol production and should be guided by symptoms and, when needed, morning cortisol or ACTH stimulation testing. The rate of taper depends on dose, duration of therapy, and individual response. Rapid dose reduction schedules risk unmasking adrenal insufficiency before the axis has recovered.

• A. Halving the dose every 3 days is too rapid after 4 months of therapy and risks adrenal insufficiency.
• B. Switching glucocorticoid type does not address the need for gradual withdrawal and abrupt stopping remains unsafe.
• C. Abrupt cessation risks adrenal crisis; routine hydrocortisone replacement is not the standard first step without evidence of adrenal insufficiency.

Primary hyperparathyroidism is characterized by elevated or inappropriately normal PTH in the presence of hypercalcemia, typically with associated hypophosphatemia due to PTH-mediated phosphate wasting. Most cases are caused by a single parathyroid adenoma. Hypercalcemia of malignancy and vitamin D intoxication both suppress PTH through negative feedback, so a frankly elevated PTH excludes these causes. Familial hypocalciuric hypercalcemia also shows elevated or normal PTH but is distinguished by a low urinary calcium-to-creatinine clearance ratio, which must be checked to exclude it.

• A. Vitamin D intoxication causes hypercalcemia with suppressed PTH and elevated phosphate.
• B. This condition typically shows a low urinary calcium-to-creatinine clearance ratio and is usually asymptomatic from childhood.
• C. Malignancy-associated hypercalcemia is usually PTH-independent, with suppressed, not elevated, PTH levels.

SIADH is characterized by hyponatremia with low serum osmolality but inappropriately concentrated urine (urine osmolality greater than serum osmolality) in a euvolemic patient, reflecting continued water retention despite low plasma tonicity. Small cell lung cancer is a classic paraneoplastic cause through ectopic ADH secretion. Diabetes insipidus, by contrast, causes polyuria with dilute urine and tends toward hypernatremia, the opposite biochemical pattern. Primary polydipsia causes dilutional hyponatremia but with appropriately dilute urine, not concentrated urine.

• A. Nephrogenic DI also produces dilute polyuria and hypernatremia, the opposite pattern seen here.
• B. Central DI causes polyuria with dilute urine and hypernatremia, not oliguria with concentrated urine and hyponatremia.
• D. Primary polydipsia causes hyponatremia with dilute urine, not concentrated urine as seen in this patient.

Severe symptomatic hyponatremia with seizures or significant neurological impairment is a medical emergency requiring prompt correction with hypertonic 3% saline, typically given as small boluses (for example 150 mL over 10-20 minutes, repeated if symptoms persist) to rapidly raise serum sodium by 4-6 mmol/L and reverse cerebral edema. Correction must be monitored closely to avoid exceeding safe limits (generally no more than 8-10 mmol/L per 24 hours) and prevent osmotic demyelination syndrome. Fluid restriction is appropriate for chronic, asymptomatic SIADH but acts too slowly for an actively seizing patient. Normal saline can paradoxically worsen hyponatremia in SIADH because the dilute urine excreted may exceed the sodium content infused.

• A. Tolvaptan is not appropriate for emergency management of seizures and carries a risk of overly rapid correction when combined with other measures.
• C. Normal saline is often ineffective or even worsens hyponatremia in SIADH due to continued free water retention.
• D. Fluid restriction is too slow for a patient with seizures and does not acutely raise serum sodium.

In central diabetes insipidus, the kidneys retain the ability to respond to antidiuretic hormone, so administering desmopressin after water deprivation causes a significant rise in urine osmolality (typically greater than 50%), confirming that the defect lies in ADH secretion rather than renal response. In nephrogenic DI, the renal tubules are unresponsive to ADH, so urine osmolality remains low even after desmopressin is given. Failure of urine to concentrate above serum osmolality during water deprivation itself confirms DI in general but does not distinguish the central from the nephrogenic type, which requires the desmopressin response.

• A. This finding would suggest a urine concentrating ability prior to desmopressin, which is inconsistent with diabetes insipidus and not the distinguishing step.
• B. This pattern of no response to desmopressin indicates nephrogenic, not central, diabetes insipidus.
• C. This is not the expected or diagnostic pattern used to distinguish the two types of DI.

Acute symptomatic hypocalcemia with tetany, a positive Chvostek sign, and ECG changes such as QT prolongation is a medical emergency requiring immediate intravenous calcium gluconate (typically 10 mL of 10% solution diluted and infused slowly) under cardiac monitoring. This rapidly raises serum ionized calcium and reverses neuromuscular irritability and the risk of arrhythmia. Post-thyroidectomy hypocalcemia results from inadvertent parathyroid gland injury or devascularization during surgery. Oral calcium and vitamin D preparations act too slowly to be appropriate for acute severe symptoms and are used for maintenance therapy afterward.

• A. Oral calcium preparations act too slowly to treat acute tetany and ECG changes.
• B. Magnesium should only be given if hypomagnesemia is contributing to the hypocalcemia, not as first-line treatment here.
• D. Calcitriol alone has a delayed onset of action and does not address the acute emergency.

Bisphosphonates such as alendronate are first-line therapy for postmenopausal osteoporosis with a T-score of -2.5 or lower, working by inhibiting osteoclast-mediated bone resorption. A recognized though uncommon adverse effect is osteonecrosis of the jaw, with risk increased by invasive dental procedures such as extractions during therapy; patients should ideally complete necessary dental work before starting treatment. Other important counseling points include esophagitis (requiring the patient to remain upright after dosing) and rare atypical femoral fractures with long-term use. Hearing loss, pancreatitis, and peripheral neuropathy are not established bisphosphonate adverse effects.

• A. Peripheral neuropathy is not a known bisphosphonate side effect.
• B. Pancreatitis is not associated with bisphosphonate use.
• D. Hearing loss is not a recognized adverse effect of bisphosphonate therapy.